FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2591843640> ?p ?o ?g. }

• W2591843640 abstract "Abstract Introduction: LR11 is a type I membrane protein that plays a key role in the migration of undifferentiated vascular smooth muscle cells, and circulating soluble LR11 (sLR11) has been known as a biomarker for coronary stenosis. We have previously found that LR11 is highly expressed in acute leukemia, diffuse large B cell lymphoma (DLBCL), and follicular lymphoma (FL) cells. Soluble LR11 were detected in the patients' serum, and our retrospective cohort demonstrated that serum sLR11 level is significantly increased at diagnosis and normalized at remission (Sakai et al. Clin Chim Acta. 2012, Ohwada et al. 2011 ASH annual meeting). Furthermore, high serum sLR11 level had a significant association with relapse and inferior progression-free survival (PFS) in patients with FL (Kawaguchi et al. Br J Haematol. 2013). Based on these findings, we have conducted a multicenter prospective observational study to validate the clinical impact of serum sLR11 in patients with newly diagnosed DLBCL. Patients and Methods: Ninety-seven consecutive patients with newly diagnosed DLBCL between 2010 and 2013 in Chiba University Hospital and affiliated hospitals were enrolled. Serum samples were collected at diagnosis and when the patients reached complete remission. Clinical and laboratorial data were collected prospectively. Serum sLR11 levels were measured with enzyme-linked immunosorbent assay. Normal control samples were obtained from 75 healthy adult volunteers who had given informed consent. Results: The patients had a median age of 69 years (range, 18-94). Ninety percent of patients were treated with R-CHOP-based regimen, and 80% of them achieved complete remission (CR). Serum sLR11 levels of DLBCL patients were significantly elevated than those of normal controls (21.2 ±27.6 ng/ml vs. 8.8 ±1.8 ng/ml, p<0.0001), and paired sample analysis showed elevated serum sLR11 level at diagnosis was significantly decreased at complete remission (17.4 ± 16.4 ng/ml vs. 11.0 ± 4.2 ng/ml, p=0.0008). Serum sLR11 levels were significantly high in poor risk patients categorized by Revised-International Prognostic Index (R-IPI) (poor vs. very-good/good: 33.0 ± 37.1 ng/ml vs. 11.0 ± 4.2 ng/ml, p<0.0001), and also in those with bone marrow invasion (present vs. absent: 48.7 ± 59.5 ng/ml vs. 17.0 ± 15.3 ng/ml, p=0.01). Multiple stepwise liner regression analysis revealed that serum sLR11 level at diagnosis was independently associated with serum LDH and beta-2-microgloblin levels (B2MG) (r2=0.43, serum LDH: p=0.0007, serum B2MG: p<0.0001). At the median follow-up period of 13.8 months, 2-year progression free survival (PFS) and overall survival (OS) were significantly inferior in patients with serum sLR11 >=18 ng/ml, compared to those with < 18 ng/ml (2-year PFS: 47% vs. 85%, p<0.0001, 2-year OS: 49% vs. 89%, p<0.0001). Furthermore, among 44 poor-risk patients determined by R-IPI, patients with serum sLR11 >=18 ng/ml showed a trend toward lower PFS than those with <18 ng/ml (2-year PFS: 41% vs. 64%, p=0.06). Conclusion: Here we have prospectively validated that serum sLR11 is a simple and powerful indicator of tumor burden and aggressive disease character with poor prognosis. By combining with previously established prognostic indexes, sLR11 may enable us to identify high-risk patients who are candidates for more aggressive treatment strategy such as up-front autologous stem cell transplantation, or combination of novel targeted agents. Figure 1 Figure 1A. OS according to serum sLR11 at diagnosis. Figure 1B. PFS in patients with Poor R-IPI risk, according to serum sLR11 at diagnosis. Figure 1. Figure 1A. OS according to serum sLR11 at diagnosis. Figure 1B. PFS in patients with Poor R-IPI risk, according to serum sLR11 at diagnosis. Disclosures No relevant conflicts of interest to declare." @default.
• W2591843640 created "2017-03-16" @default.
• W2591843640 creator A5004170848 @default.
• W2591843640 creator A5004483807 @default.
• W2591843640 creator A5013112172 @default.
• W2591843640 creator A5013237347 @default.
• W2591843640 creator A5015191243 @default.
• W2591843640 creator A5023513766 @default.
• W2591843640 creator A5027289927 @default.
• W2591843640 creator A5027496527 @default.
• W2591843640 creator A5032036038 @default.
• W2591843640 creator A5035797354 @default.
• W2591843640 creator A5041674771 @default.
• W2591843640 creator A5043562194 @default.
• W2591843640 creator A5047821211 @default.
• W2591843640 creator A5048967405 @default.
• W2591843640 creator A5065276140 @default.
• W2591843640 creator A5068249765 @default.
• W2591843640 creator A5073984471 @default.
• W2591843640 creator A5076192129 @default.
• W2591843640 creator A5082010384 @default.
• W2591843640 creator A5084385524 @default.
• W2591843640 creator A5087064074 @default.
• W2591843640 date "2014-12-06" @default.
• W2591843640 modified "2023-10-01" @default.
• W2591843640 title "Impact of Serum Soluble LR11 on Survival in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Multicenter Prospective Study" @default.
• W2591843640 doi "https://doi.org/10.1182/blood.v124.21.1661.1661" @default.
• W2591843640 hasPublicationYear "2014" @default.
• W2591843640 type Work @default.
• W2591843640 sameAs 2591843640 @default.
• W2591843640 citedByCount "0" @default.
• W2591843640 crossrefType "journal-article" @default.
• W2591843640 hasAuthorship W2591843640A5004170848 @default.
• W2591843640 hasAuthorship W2591843640A5004483807 @default.
• W2591843640 hasAuthorship W2591843640A5013112172 @default.
• W2591843640 hasAuthorship W2591843640A5013237347 @default.
• W2591843640 hasAuthorship W2591843640A5015191243 @default.
• W2591843640 hasAuthorship W2591843640A5023513766 @default.
• W2591843640 hasAuthorship W2591843640A5027289927 @default.
• W2591843640 hasAuthorship W2591843640A5027496527 @default.
• W2591843640 hasAuthorship W2591843640A5032036038 @default.
• W2591843640 hasAuthorship W2591843640A5035797354 @default.
• W2591843640 hasAuthorship W2591843640A5041674771 @default.
• W2591843640 hasAuthorship W2591843640A5043562194 @default.
• W2591843640 hasAuthorship W2591843640A5047821211 @default.
• W2591843640 hasAuthorship W2591843640A5048967405 @default.
• W2591843640 hasAuthorship W2591843640A5065276140 @default.
• W2591843640 hasAuthorship W2591843640A5068249765 @default.
• W2591843640 hasAuthorship W2591843640A5073984471 @default.
• W2591843640 hasAuthorship W2591843640A5076192129 @default.
• W2591843640 hasAuthorship W2591843640A5082010384 @default.
• W2591843640 hasAuthorship W2591843640A5084385524 @default.
• W2591843640 hasAuthorship W2591843640A5087064074 @default.
• W2591843640 hasConcept C126322002 @default.
• W2591843640 hasConcept C188816634 @default.
• W2591843640 hasConcept C2777058707 @default.
• W2591843640 hasConcept C2778559949 @default.
• W2591843640 hasConcept C2779338263 @default.
• W2591843640 hasConcept C2781197716 @default.
• W2591843640 hasConcept C2781413609 @default.
• W2591843640 hasConcept C55493867 @default.
• W2591843640 hasConcept C71924100 @default.
• W2591843640 hasConcept C86803240 @default.
• W2591843640 hasConcept C90924648 @default.
• W2591843640 hasConceptScore W2591843640C126322002 @default.
• W2591843640 hasConceptScore W2591843640C188816634 @default.
• W2591843640 hasConceptScore W2591843640C2777058707 @default.
• W2591843640 hasConceptScore W2591843640C2778559949 @default.
• W2591843640 hasConceptScore W2591843640C2779338263 @default.
• W2591843640 hasConceptScore W2591843640C2781197716 @default.
• W2591843640 hasConceptScore W2591843640C2781413609 @default.
• W2591843640 hasConceptScore W2591843640C55493867 @default.
• W2591843640 hasConceptScore W2591843640C71924100 @default.
• W2591843640 hasConceptScore W2591843640C86803240 @default.
• W2591843640 hasConceptScore W2591843640C90924648 @default.
• W2591843640 hasLocation W25918436401 @default.
• W2591843640 hasOpenAccess W2591843640 @default.
• W2591843640 hasPrimaryLocation W25918436401 @default.
• W2591843640 hasRelatedWork W1204612610 @default.
• W2591843640 hasRelatedWork W1710561286 @default.
• W2591843640 hasRelatedWork W2085802369 @default.
• W2591843640 hasRelatedWork W2117488094 @default.
• W2591843640 hasRelatedWork W2151555749 @default.
• W2591843640 hasRelatedWork W2246946424 @default.
• W2591843640 hasRelatedWork W2357365210 @default.
• W2591843640 hasRelatedWork W2379059049 @default.
• W2591843640 hasRelatedWork W2430696893 @default.
• W2591843640 hasRelatedWork W2507314542 @default.
• W2591843640 hasRelatedWork W2556136813 @default.
• W2591843640 hasRelatedWork W2560008212 @default.
• W2591843640 hasRelatedWork W2572377863 @default.
• W2591843640 hasRelatedWork W2595187812 @default.
• W2591843640 hasRelatedWork W2794476713 @default.
• W2591843640 hasRelatedWork W2959948243 @default.
• W2591843640 hasRelatedWork W3087270458 @default.
• W2591843640 hasRelatedWork W3111034560 @default.
• W2591843640 hasRelatedWork W3112322925 @default.
• W2591843640 hasRelatedWork W6890951 @default.
• W2591843640 isParatext "false" @default.
• W2591843640 isRetracted "false" @default.

• next